Private Advisor Group’s ProQR Therapeutics PRQR Stock Holding History

Private Advisor Group’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,160	Closed	-$13K	–	2946
2020 Q2	$13K	Buy	+2,160	New	+$11.7K	﹤0.01%	2804

Other funds holding PRQR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Private Advisor Group's PRQR Position: Q3 2020 in Review

Private Advisor Group sold out of ProQR Therapeutics (PRQR) in Q3 2020, closing a stake of 2,160 shares — an estimated $13K sold.

Private Advisor Group first reported a position in PRQR in Q2 2020 and held it in 1 quarter. The position peaked at $13K in Q2 2020. 42 funds tracked by Wall St. Rank hold PRQR as of Q3 2020.

Private Advisor Group reported no remaining ProQR Therapeutics position as of Q3 2020 after selling out during the quarter.
Private Advisor Group sold 2,160 ProQR Therapeutics shares in Q3 2020, an estimated $13K.
Private Advisor Group first reported a position in ProQR Therapeutics in Q2 2020 and held it in 1 quarter.
Private Advisor Group's ProQR Therapeutics position peaked at $13K in Q2 2020.
42 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.